{"created":"2023-05-15T09:48:36.239310+00:00","id":11466,"links":{},"metadata":{"_buckets":{"deposit":"06e928b0-0416-475d-9264-5a77efcb01af"},"_deposit":{"created_by":11,"id":"11466","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"11466"},"status":"published"},"_oai":{"id":"oai:kagawa-u.repo.nii.ac.jp:00011466","sets":["13:40"]},"author_link":["3973"],"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2022-09-21"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"香川大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Kagawa University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"16201","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Patients and methods: Patients with advanced pancreatic cancer were treated with varying doses of FOLFIRINOX to determine the optimum dosage for highest remission outcomes with the least post-chemotherapy toxicities.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results: Patients given 180 mg of irinotecan and a 400 mg bolus of 5-fluorouracil (5-FU) showed a marked difference in outcome when compared to irinotecan 180 mg given without the 5-FU bolus, with the overall response rate being 28%, a survival time of 6.4 months and progression-free survival time of 4.5 months.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion: The optimum dose of FOLFIRINOX was a dosage combination of oxaliplatin 85 mg/m 2 , irinotecan 180 mg/m 2 , l-leucovorin 400 mg/m 2 and 5-FU 2,400 mg/m 2 , administered as a continuous 46-h infusion.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"乙第299号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.21873/cdp.10083","subitem_relation_type_select":"DOI"}},{"subitem_relation_type":"hasVersion","subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8962842/","subitem_relation_type_select":"URI"}}]},"item_10006_relation_22":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"35400007","subitem_relation_type_select":"PMID"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 2022, International Institute of Anticancer Research.","subitem_rights_language":"en"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_fa2ee174bc00049f","subitem_version_type":"P"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"籏智, 幸政","creatorNameLang":"ja"},{"creatorName":"ハタチ, ユキマサ","creatorNameLang":"ja-Kana"},{"creatorName":"Hatachi, Yukimasa","creatorNameLang":"en"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-10-18"}],"displaytype":"detail","filename":"Med_B299.pdf","filesize":[{"value":"317.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"本文","objectType":"fulltext","url":"https://kagawa-u.repo.nii.ac.jp/record/11466/files/Med_B299.pdf"},"version_id":"f4eb8be1-f6b6-4516-995f-001b06425db7"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-10-18"}],"displaytype":"detail","filename":"Med_B299_abstract.pdf","filesize":[{"value":"52.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","objectType":"abstract","url":"https://kagawa-u.repo.nii.ac.jp/record/11466/files/Med_B299_abstract.pdf"},"version_id":"407ac47f-dac1-4c85-a743-4854455c69ae"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-10-18"}],"displaytype":"detail","filename":"Med_B299_result.pdf","filesize":[{"value":"88.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査の結果の要旨","objectType":"other","url":"https://kagawa-u.repo.nii.ac.jp/record/11466/files/Med_B299_result.pdf"},"version_id":"ea7792de-b4e4-4220-9832-b544a0692d90"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"FOLFIRINOX","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"pancreatic cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"optimal dose","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"dose limiting toxicity","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)","subitem_title_language":"en"}]},"item_type_id":"10006","owner":"11","path":["40"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-10-18"},"publish_date":"2022-10-18","publish_status":"0","recid":"11466","relation_version_is_last":true,"title":["FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-10-16T02:32:28.704831+00:00"}